An implantable bioartificial kidney is similar to existing extracorporeal renal assist device (RAD), which is a bioartificial kidney that combines a membrane hemofilter and a bioreactor to function as a healthy kidney. However, to work as a natural kidney, the bioartificial kidney should have high efficiency ultrafiltration membranes, should be able to regulate blood flow, and stabilize necessary cells. Implantable bioartificial kidney is capable of replicating the work of real kidney and can eliminate the need for dialysis. Implantable bioartificial kidney avoids constant physician oversight and need to take immunosuppressant drugs and medication.
Implantable Bioartificial Kidney Market: Drivers
Increasing number of chronic kidney disease patients, rising number of kidney failure incidences, and long waiting list for kidney transplants is expected to boost the global implantable bioartificial kidney market growth over the forecast period. For instance, according to Kidney Health Australia, 2010, the cost of treating all current and new cases of End Stage Kidney Disease (ESKD) will reach up to US$ 12 billion by 2020. Moreover, according to the Centers for Disease Control & Prevention (CDC), around 15% of the adults in the U.S. were estimated to have chronic kidney disease in 2017. CDC states that around 96% of the people with kidney damage or hampered kidney function are not aware of having chronic kidney disease. These factors are expected to drive the global implantable bioartificial kidney market growth over the forecast period.
Individual government organizations and manufacturers are working towards increasing the awareness of kidney diseases. For instance, American Kidney Fund (AKF) launched a comprehensive new kidney disease education portal in May 2018. The education portal called as ‘CKD Central’ will provide information and resources on chronic kidney disease (CKD). Moreover, The Kidney Project is a national research project, which aims to create a small, surgically implanted, and free-standing bioartificial kidney to treat end stage renal disease (ESRD). This kidney is expected to provide ESRD patients with a new option beyond the short-term solution of renal dialysis and the costly kidney transplant for which donor organs are limited.
Stringent regulatory policies for the approval and manufacturing, reimbursement, and risks and complications associated with dialysis treatment are expected to restrain the global implantable bioartificial kidney market growth over the forecast period.
Implantable Bioartificial Kidney Market: Regional Analysis
North America implantable bioartificial kidney market is expected to hold dominant position in the global market over the forecast period. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), over 661,000 people in the U.S. had kidney failure and of these, 468,000 individuals were on dialysis, in 2017. The kidney project, headed by researchers from the University of California San Francisco (UCSF), the University of Vanderbilt, and the National Institute of Biomedical Imaging and Bioengineering (NIBIB), is expected to receive approval for the artificial kidney trials by late 2018 or early 2019. These factors are expected to support the North America implantable bioartificial kidney market growth over the forecast period. According to report of Brazilian Transplant Registry, 2016, Brazil accounts for the second largest number of kidney transplant programs in the world.
Implantable Bioartificial Kidney Market: Taxonomy
The global implantable bioartificial kidney market is segmented on the basis of end user, and region.
By End User:
- Organ Transplant Centers
- North America
- Latin America
- Asia Pacific
- Middle East